Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2015, Article ID 146972, 8 pages
Review Article

Current Review of Genetically Modified Lactic Acid Bacteria for the Prevention and Treatment of Colitis Using Murine Models

1Centro de Referencia para Lactobacilos (CERELA-CONICET), T4000ILC San Miguel de Tucumán, Argentina
2INRA, Commensal and Probiotics-Host Interactions Laboratory, UMR1319 Micalis, 78350 Jouy-en-Josas, France
3AgroParisTech, UMR1319 Micalis, 78350 Jouy-en-Josas, France
4Federal University of Minas Gerais (UFMG), 31270-901 Belo Horizonte, MG, Brazil

Received 23 November 2014; Revised 21 April 2015; Accepted 22 April 2015

Academic Editor: Mohamed Othman

Copyright © 2015 Alejandra de Moreno de LeBlanc et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Inflammatory Bowel Diseases (IBD) are disorders of the gastrointestinal tract characterized by recurrent inflammation that requires lifelong treatments. Probiotic microorganisms appear as an alternative for these patients; however, probiotic characteristics are strain dependent and each probiotic needs to be tested to understand the underlining mechanisms involved in their beneficial properties. Genetic modification of lactic acid bacteria (LAB) was also described as a tool for new IBD treatments. The first part of this review shows different genetically modified LAB (GM-LAB) described for IBD treatment since 2000. Then, the two principally studied strategies are discussed (i) GM-LAB producing antioxidant enzymes and (ii) GM-LAB producing the anti-inflammatory cytokine IL-10. Different delivery systems, including protein delivery and DNA delivery, will also be discussed. Studies show the efficacy of GM-LAB (using different expression systems) for the prevention and treatment of IBD, highlighting the importance of the bacterial strain selection (with anti-inflammatory innate properties) as a promising alternative. These microorganisms could be used in the near future for the development of therapeutic products with anti-inflammatory properties that can improve the quality of life of IBD patients.